Pediatric Exclusivity Bill Expected To Be Signed Into Law By Year-End
This article was originally published in The Tan Sheet
Executive Summary
Legislation reauthorizing the pediatric exclusivity provisions of the FDA Modernization Act will close a loophole involving incidents where 180-day generic exclusivity and pediatric exclusivity overlap
You may also be interested in...
Pediatric research
User fee exemption for pediatric drug supplements repealed under "Best Pharmaceuticals for Children Act," signed by President Bush Jan. 4. Under the law, which reauthorizes pediatric exclusivity provisions, all pediatric supplements that require clinical data for approvals, even if the supplement is for a new indication, must pay fees unless otherwise eligible for waivers. Law also directs FDA not to delay ANDA approvals based on pediatric labeling disputes (1"The Tan Sheet" Nov. 26, 2001, p. 21)...
Pediatric research
User fee exemption for pediatric drug supplements repealed under "Best Pharmaceuticals for Children Act," signed by President Bush Jan. 4. Under the law, which reauthorizes pediatric exclusivity provisions, all pediatric supplements that require clinical data for approvals, even if the supplement is for a new indication, must pay fees unless otherwise eligible for waivers. Law also directs FDA not to delay ANDA approvals based on pediatric labeling disputes (1"The Tan Sheet" Nov. 26, 2001, p. 21)...
Pediatric research
User fee exemption for pediatric drug supplements repealed under "Best Pharmaceuticals for Children Act," signed by President Bush Jan. 4. Under the law, which reauthorizes pediatric exclusivity provisions, all pediatric supplements that require clinical data for approvals, even if the supplement is for a new indication, must pay fees unless otherwise eligible for waivers. Law also directs FDA not to delay ANDA approvals based on pediatric labeling disputes (1"The Tan Sheet" Nov. 26, 2001, p. 21)...